Notably, we observed the over-expression of TOP2A, a potential chemotherapeutic target [51], CCND1, a potential target for CDK4/6 inhibitors with ongoing clinical studies in NB patients (NCT05429502, NCT01747876) and MDM2, which has attracted attention with the development of numerous small molecule inhibitors [52]. Here, TOP2A is linked to neuroblastoma.